by Comite Web | Oct 20, 2026 | Sin categorizar
5th ALIPANC Charity Gala
Friday, November 20, at 8:00 p.m.
Real Casino de Madrid
C. Alcalá, 15, Centro, 28014 Madrid
Donation: 200 € per person
Join the fight against pancreatic cancer
On behalf of the Pancreatic Cancer Research Alliance in Spain (ALIPANC), we would like to invite you to participate in the 5th edition of our Charity Gala, a fundraising event held in conjunction with International Pancreatic Cancer Day.
This dinner aims to:
- Raise awareness about ALIPANC’s mission
- Collect funds for research
- Strengthen the commitment of our benefactors
ALIPANC brings together over 160 researchers from Spain and Portugal, working across hospitals and research centers in multicenter, multidisciplinary studies to improve the diagnosis, treatment, and survival of pancreatic cancer patients.
How can you help?
- Attend the gala: Share a meaningful evening with researchers, patients, and representatives from the business and public sectors.
- Support through “fila cero”: Contribute even if you cannot attend in person.
- Spread the word: Help raise public awareness about this disease.
Registration
Registration form https://forms.gle/EDhZkmVo7axLodzRA
Payment Options
- Bank transfer
IBAN: ES31 0182 9769 5102 0055 3107 - Bizum (Donate to NGOs):
Code: NGO 10456
Formal attire requested.
by Comite Web | Oct 20, 2026 | Sin categorizar
A 3-day “meet the expert” International Course
January 21–23, 2027
CNIO Auditorium, Madrid, Spain
This three-day international course will bring together leading experts in pancreatic pathology, cancer biology, translational research, molecular genetics, artificial intelligence, spatial omics, and mouse models of pancreatic diseases. The program will include lectures, interactive discussions, case-based learning, and networking opportunities with internationally renowned faculty.
REGISTRATION: https://forms.gle/mfxtwpugFNaT9Voz6
PROGRAMME: Download
by Comite Web | Oct 16, 2026 | Sin categorizar
A study led by ALIPANC researchers from the Maimonides Biomedical Research Institute of Cordoba (IMIBIC) and the University of Córdoba (UCO) has provided the first comprehensive RNA spliceosomic landscape of pancreatic neuroendocrine tumors (PanNETs). The results, published in Endocrine Pathology, show through integrative transcriptomic analysis of 174 tumor samples that PanNETs can be classified into three robust spliceosomic subgroups (SPN1, SPN2, and SPN3) with distinct clinical, molecular, and biological behavior.
The study reveals an unprecedented discovery in these tumors: a direct association between the expression profile of the splicing machinery and its functional product, the alternative splicing variants. Specifically, SPN1 exhibits intermediate clinical behavior alongside enhanced mTOR signaling; SPN2 is characterized by a less secretory phenotype, enriched alpha-cell markers and somatostatin receptors (SSTR), higher metastasis, and frequent mutations in MEN1 and DAXX/ATRX; while SPN3 comprises mainly low-grade tumors with beta-cell markers, the lowest mutational rate, and all highly proliferative neoplasms.
Furthermore, the results demonstrate that alterations in specific splicing factor families condition distinct RNA splicing events that affect key signaling, metabolic, and regulatory pathways. This integrative approach deepens the understanding of PanNET molecular heterogeneity and establishes RNA splicing profiling as a promising foundation for discovering novel biomarkers and developing personalized therapeutic strategies.
Reference article:
Ricardo Blázquez-Encinas, Víctor García-Vioque, Andrea Mafficini, Luca Landoni, Daniel Ruiz-Palacios, Laura Gutiérrez-Camacho, María Trinidad Moreno-Montilla, Nicolás Alcalá, Sebastián Ventura, Eduardo Eyras, Salvatore Paiella, Roberto Salvia, Vita Rovite, Matthieu Foll, Claudio Luchini, Lynnette Fernandez-Cuesta, Rita T. Lawlor, Aldo Scarpa, Alejandro Ibáñez-Costa, Sergio Pedraza-Arevalo, Justo P. Castaño. An Integrative RNA Spliceosomic Landscape of Pancreatic Neuroendocrine Tumors Identifies Clinically Relevant Molecular Subgroups. Endocrine Pathology 2026; 37:28. https://doi.org/10.1007/s12022-026-09923-1
by Comite Web | Oct 1, 2026 | Sin categorizar
Speaker: Dr. Remy Nicolley
Institution: Pancreatic Cancer Heterogeneity & Translational Genomics Group | Center for Inflammation Research | Paris, France
Title:“Morphomolecular Phenotyping of Pancreatic Tumors”
Description
On October 15 at 3:00 p.m. CET, ALIPANC will hold another session of the ALIPANC Seminar Series, an initiative designed to promote scientific exchange and highlight the most innovative advances in pancreatic cancer research.
Dr. Remy Nicolle is the principal investigator of the
Pancreatic Cancer Heterogeneity & Translational Genomics group at the
Centre de Recherche sur l’Inflammation (INSERM, Paris, France).
Access
This seminar is open to the public; the registration link will be shared shortly.
For any additional information, please contact info@alipanc.org to request the meeting link.
by Comite Web | Sep 17, 2026 | Sin categorizar
An international team—with significant participation from the PADO group at the ICO and IDIBELL, which includes several members of ALIPANC—has developed an epidemiological risk score for the early detection of pancreatic cancer, one of the deadliest cancers due to late diagnosis. The study, published in the International Journal of Epidemiology, is based on 24 known risk factors—such as age, smoking, diabetes, chronic pancreatitis, and family history—which help identify individuals most likely to develop the disease. The score was applied to a prospective cohort of 178 individuals with a high family risk from four European centers, as part of the IMAGene project, who were evaluated using magnetic resonance imaging. The results show that higher scores were associated with a greater number of potentially malignant lesions. External validation, conducted with nearly 300,000 participants from the UK Biobank, confirmed these associations. The authors conclude that this could be a feasible, noninvasive, and low-cost tool for risk stratification, although further studies will be needed before it can be applied clinically.
PMID: 42160519
doi: 10.1093/ije/dyag064
by Comite Web | Sep 17, 2026 | Sin categorizar
The multicenter study included 672 patients treated with first-line chemotherapy. A low SIRI score (≤2.3) was associated with longer overall survival (14.0 vs. 9.2 months). It was also associated with longer progression-free survival (5.9 vs. 3.9 months) and a higher tumor response rate (37% vs. 25%). In addition to the classic cutoff point, the SIRI was analyzed as a continuous variable. This analysis revealed a nonlinear relationship between increasing SIRI and a worse prognosis. A high SIRI score was also associated with a higher hepatic tumor burden and cachexia.
An open-access web calculator allows users to explore this continuous prognostic gradient on an individualized basis: https://pantheia-siri.shinyapps.io/calc/.
The collaborative study was led by Vilma Pacheco-Barcia and has been published in the journals *Pancreatology* and *Clinical Translational Oncology*.
PMID 42601286, 42690293
doi: 10.1016/j.pan.2026.08.008
doi: 10.1007/s12094-026-04554-8
